Group Members

Jochen K Lennerz, MD, PhD

Medical Director, Center for Integrated Diagnostics, Massachusetts General Hospital
Assistant Professor of Pathology, Harvard Medical School

Dr. Lennerz is board-certified in Anatomic-and Molecular Genetic Pathology and joined Mass General Department of Pathology and Center for Integrated Diagnostics as a staff pathologist and assistant professor in 2014.  Dr. Lennerz trained as a pathologist assistant in Berlin Germany (1994) and studied both medicine and molecular medicine at the University Erlangen Germany where he also received his MD, PhD.  He did his residency training in Anatomic Pathology (2008) and a fellowship in Molecular Genetic Pathology (2009) at Washington University in St. Louis.  After completion of a two-year gastrointestinal and liver pathology fellowship at Mass General (2011), he led a research group on biomarkers in lymphoma at Ulm University Germany.  Dr. Lennerz joined the CID in 2014 and his interests are biomarkers, digital pathology, and financial sustainability of molecular genetic diagnostics.

A. John Iafrate, MD, PhD

Professor of Pathology, Massachusetts General Hospital
Professor of Pathology, Harvard Medical School
Vice Chair of Academic Affairs

Dr. Iafrate is a board-certified pathologist who joined Mass General in 2005. He formerly directed the Center for Integrated Diagnostics at Mass General and oversees a translational research laboratory that supports both Pathology and the Mass General Cancer Center. He is an MD, PhD, having received his dual degree from the State University of New York at Stony Brook in 2000 and was trained in Anatomic and Molecular Genetic Pathology at Brigham and Women’s Hospital. His post-doctoral work involved the discovery and description of a novel source of human genetic diversity termed copy number variation (CNV). Since arriving at MGH, he has established a cancer diagnostics lab focusing on genetic fingerprints that help guide novel targeted therapies. His laboratory launched SNAPSHOT several years ago, an assay that tests over 100 of the most common mutations in tumors. His research is focused on lung and brain tumors, and he has been closely involved in the clinical development of crizotinib and companion diagnostics in ALK-positive lung cancers. 


Long Phi Le, MD, PhD

Assistant in Pathology, Massachusetts General Hospital
Assistant Professor of Pathology, Harvard Medical School
Director of Computational Pathology 

Dr. Le is a graduate of Massachusetts Institute of Technology (1999) and received his MD, PhD from the University of Alabama at Birmingham School of Medicine in 2006.  He completed his residency training in Clinical Pathology at the Massachusetts General Hospital and his Molecular Genetic Pathology Fellowship at Brigham and Women's Hospital (2010).  He joined the Mass General Department of Pathology as an instructor and assistant pathologist in 2010.  His clinical and research interests in the Diagnostic Molecular Pathology Laboratory include the application of copy number analysis, next generation sequencing, and bioinformatics in molecular diagnostics.


Gad A. Getz, Ph.D

Director, Bioinformatics Program, Massachusetts General Hospital Cancer Center and Department of Pathology
Paul C. Zamecnik Chair of Oncology, Massachusetts General Hospital Cancer Center
Associate Professor of Pathology, Harvard Medical School
Director, Cancer Genome Computational Analysis, Broad Institute

Dr. Getz is an internationally acclaimed leader in cancer genome analysis and is pioneering widely used cancer genome analysis tools. Dr. Getz joined the Mass General staff in 2013. He directs the Bioinformatics Program at the Mass General Cancer Center and Department of Pathology. Getz is also the inaugural incumbent of the Paul C. Zamecnik Chair of Oncology at the Mass General Cancer Center. In addition to his role at the Massachusetts General Hospital, Getz directs the Cancer Genome Computational Analysis group at the Broad Institute. He has published numerous papers in prominent journals that describe new genes and pathways involved in different tumor types. Getz received his B.S. degree in Physics and Mathematics from Hebrew University and an M.Sc. in Physics from Tel-Aviv University. He later earned a PhD in Physics from the Weizmann Institute of Science in Israel. He completed his postdoctoral training at the Broad Institute of MIT and Harvard with Todd Golub, where he focused on developing computational tools and analyzing expression of miRNAs across cancer.


Dora Dias-Santagata, PhD, FACMG

Assistant Molecular Pathologist, Massachusetts General Hospital
Assistant Professor of Pathology, Harvard Medical School

Dr. Dias-Santagata is board-certified in Clinical Molecular Genetics and joined the Mass General staff in 2007 to co-direct the Translational Research Laboratory, a mutual collaboration between the Mass General Department of Pathology and the Cancer Center. She received her PhD from the Mount Sinai School of Medicine in New York (2004), and pursued post-doctoral research work at the Brigham and Women’s Hospital in Boston. She developed and co-directed the clinical implementation of SNaPshot, a pioneering tumor genotyping strategy that has been adopted by the oncology community at Mass General since March 2009, to help guide therapeutic decisions. Her research efforts include the molecular characterization of rare malignancies, lung and thyroid cancers, in an effort to uncover underlying genetic driver amenable for therapeutic intervention and mechanisms of acquired resistance to therapy. 


Darrell R. Borger, PhD

Assistant in Biology, Massachusetts General Hospital
Instructor in Medicine, Harvard Medical School

Dr. Borger received his PhD from the University of South Carolina, School of Medicine in Biomedical Science and then received post-doctoral training at the Dana-Farber Cancer Institute, where he identified basic mechanisms that drive cancer development and promote drug resistance. At Mass General, he has helped develop cutting-edge clinical testing platforms that provide genetic “fingerprinting” of patient tumor tissue that is used to support a personalized approach to cancer therapy. As Director of the Translational Research Laboratory, Biomarker Unit, he is developing novel approaches that can help rationally direct patients to experimental cancer therapy trials based on an underlying tumor biomarker. Dr. Borger’s research interests also include identifying new tumor biomarkers that may expand treatment options for cancer patients and identifying mechanisms that promote drug resistance. He has also played a major role in developing a new website that provides disease-specific information on how tumor genotyping can direct cancer care and identify specific trials accruing patients at the Mass General that that are matched to a specific cancer type or genotyping test result. (


Miguel N. Rivera, MD

Assistant in Pathology, Massachusetts General Hospital
Assistant Professor of Pathology, Harvard Medical School

Dr. Rivera is a board certified pathologist who directs a research laboratory at the Mass General Department of Pathology and the Mass General Cancer Center. He also serves as attending physician in the Center for Integrated Diagnostics at Mass General. Dr. Rivera received an AB in Molecular Biology from Princeton University in 1996 and an MD from Harvard Medical School in 2001. He completed his Anatomic Pathology residency at Brigham and Women’s Hospital and a fellowship in Molecular Diagnostics at the Harvard Combined Program. During his postdoctoral fellowship, Dr. Rivera identified the tumor suppressor gene WTX which is implicated in both tumor formation and stem cell biology. His research currently focuses on the connections between cancer and normal developmental processes and on the use of genomic technologies to identify pathways that are active in tumors and that may serve as therapeutic targets.


Valentina Nardi, MD

Assistant in Pathology, Massachusetts General Hospital
Instructor, Harvard Medical School

Dr. Nardi received her MD degree and board certification in Hematology in Genoa, Italy. She pursued post-doctoral research in Boston, under the supervision of Dr. George Daley at Children's Hospital Boston, developing an interest and expertise in chronic myeloid leukemia, resistance to targeted therapies, and development and applications of new technologies to detect and monitor drug resistance over time. Dr. Nardi developed an interest in molecular diagnostics and went on to complete her Anatomic Pathology residency and a Hematopathology fellowship at the Massachusetts General Hospital and the Harvard Medical School Molecular Genetic Pathology Fellowship.


Leadership Team

Julie Miller Batten, MLS (ASCP)
Clinical Laboratory Supervisor, Center for Integrated Diagnostics

A. Bernard Collins
Outreach and Clinical Affiliates Manager, Department of Pathology
Technical Director, Research and Development Immunopathology Unit
Associate in Pathology, Harvard Medical School

Nick Jessop
Center for Integrated Diagnostics

Kathy Vernovsky, MB (ASCP)
Compliance and Quality Specialist, Center for Integrated Diagnostics


For Technical Questions: 617-643-2716

For Billing, Specimen Submission, and Testing Status Questions: 617-724-1285